对照研究布地奈德气雾剂联合茶碱缓释片组与信必可组治疗支气管哮喘的疗效及卫生经济学评价

Comparative Study of Budesonide Aerosol Combined with Theophylline Sustained Release Tablets Group and Xinbike Group in the Treatment of Bronchial Asthma Efficacy and Health Economics Evaluation

目的:对照研究布地奈德气雾剂联合茶碱缓释片组与信必可组治疗支气管哮喘的疗效及卫生经济学评价。方法:160例患者随机分为两组,每组80例,观察组采用国产布地奈德气雾剂联合茶碱缓释片治疗,对照组采用布地奈德/福莫特罗粉吸入剂治疗。结果:观察组与对照组之间哮喘控制率、不良反应发生率差异均无统计学意义(P>0.05);观察组平均费用明显低于对照组,两组间差异有统计学意义(P<0.05)。结论:布地奈德气雾剂联合茶碱缓释片组与信必可组治疗支气管哮喘对照分析两组均疗效确切,但观察组费用较低,尤其适用于基层医院患者。

Objective:To compare the efficacy and health economics evaluation of budesonide aerosol combined with theophylline sustained-release tablets and xinbike in the treatment of bronchial asthma.Methods:160 patients were randomly divided into 2 groups,80 patients in each group.The observation group was treated with domestic budesonide aerosol combined with theophylline sustained-release tablets,and the control group was treated with budesonide/formoterol powder inhalation.Results:There were no statistically significant differences in asthma control rate and incidence of adverse reactions between the observation group and the control group(P>0.05).The average cost of the observation group was significantly lower than that of the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion:The efficacy of budesonide aerosol combined with theophylline sustained-release tablets and xinbike group in the treatment of bronchial asthma was exact,but the cost of the observation group was economic and worthy of promotion,especially for patients in basic hospitals.